1. Immobilized CD155/PVR Protein, Human, Recombinant (hFc) (Cat#TMPY-00699) at 2μg/mL (100μL/well) can bind TIGIT Dimer Protein, Human, Recombinant (His) (Cat#TMPY-07043), the EC50 is 6-18 ng/mL.
2. Immobilized Anti-Tigit Antibody, Human IgG1 (Tiragolumab) at 2 μg/mL (100 μL/well) can bind TIGIT Dimer Protein, Human, Recombinant (His) (Cat#TMPY-07043), the EC50 is 1.2-4 ng/mL (Routinely tested).
3. Loaded CD155/PVR Protein, Human, Recombinant (hFc) (Cat#TMPY-00699) on ProA Biosensor, can bind TIGIT Dimer Protein, Human, Recombinant (His) (Cat#TMPY-07043) with an affinity constant of 0.51 nM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested).
4. CD155/PVR Protein, Human, Recombinant (hFc) (Cat#TMPY-00699) captured on Protein A chip can bind TIGIT Dimer Protein, Human, Recombinant (His) (Cat#TMPY-07043) with an affinity constant of 3.28 nM as determined in an SPR assay (Biacore 8K) (Routinely tested).

TIGIT Dimer Protein, Human, Recombinant (His) is expressed in HEK293 Cells. The accession number is Q495A1-1.

Human

HEK293 Cells

WUCAM,VSTM3,VSIG9,FLJ39873,DKFZp667A205

A DNA sequence encoding the extracellular domain of human TIGIT (NP_776160.2) (Met22-Pro141) with a C-terminal polyhistidine tag was expressed. This construct has a dimer design.

≥ 95% as determined by SDS-PAGE. ≥ 95% as determined by SEC-HPLC.

Please refer to the lot-specific COA.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

TIGIT, also known as V-set and transmembrane domain-containing protein 3 (VSTM3) or V-set and immunoglobulin domain-containing protein 9 (VSIG9) is a new surface protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on regulatory, memory, activated T cells and NK cells. It binds PVR with high affinity, and PVRL2 with lower affinity, but not PVRL3. Knockdown of TIGIT with siRNA in human memory T cells did not affect T cell responses, however, TIGIT inhibits NK cytotoxicity directly through its ITIM. TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. The binding of PVR to TIGIT on human dendritic cells enhanced the production of IL-1 and diminished the production of IL-12p4. Also, TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint TargetsImmunotherapyTargeted Therapy